Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.74 USD | -4.94% | -15.11% | -34.63% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.63% | 194M | |
+6.88% | 217B | |
+10.63% | 190B | |
+18.16% | 141B | |
+29.70% | 110B | |
+2.09% | 64.8B | |
+14.14% | 52.44B | |
+3.01% | 49.94B | |
+4.64% | 42.63B | |
+1.45% | 35.81B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Transcript : NeuroPace, Inc., Q4 2021 Earnings Call, Mar 10, 2022